NCT01897571 2024-03-26
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
Phase 1/2 Completed
Clinical Trials
3 trialsNCT03456726 2022-12-16
Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Eisai Inc.
Phase 2 Completed
NCT03009344 2022-11-10
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Eisai Inc.
Phase 1 Completed